预约演示
更新于：2026-08-03
Vortioxetine Hydrobromide
氢溴酸伏硫西汀
更新于：2026-08-03
概要
基本信息
药物类型 小分子化药 |
别名 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine monohydrobromide、VHDT、VORTIOXETINE + [18] |
作用方式 激动剂、拮抗剂、抑制剂 |
作用机制 5-HT1A receptor激动剂(5-羟色胺1A受体激动剂)、5-HT1B receptor激动剂(5-羟色胺1B受体激动剂)、5-HT1D receptor拮抗剂(5-羟色胺1D受体拮抗剂) |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2013-09-30), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C18H23BrN2S |
InChIKeyVNGRUFUIHGGOOM-UHFFFAOYSA-N |
CAS号960203-27-4 |
关联
189
项与 氢溴酸伏硫西汀 相关的临床试验NCT07284628
A Phase II Drug Repurposing Trial of Vortioxetine for the Treatment of Patients With Newly Diagnosed Glioblastoma
CTR20261907
氢溴酸伏硫西汀片生物等效性试验
CTR20260729
VHDT口崩片在健康人体空腹和餐后条件下的生物等效性试验
100 项与 氢溴酸伏硫西汀 相关的临床结果
登录后查看更多信息
100 项与 氢溴酸伏硫西汀 相关的转化医学
登录后查看更多信息
100 项与 氢溴酸伏硫西汀 相关的专利（医药）
登录后查看更多信息
1,015
项与 氢溴酸伏硫西汀 相关的文献（医药）2026-10-01PHYSIOLOGY & BEHAVIOR
Vortioxetine transiently alters basal locomotor activity but does not produce sedation in rats
Article
作者: Salazar-Juárez, Alberto ; Barbosa-Méndez, Susana
Sedation is a major side effect of many pharmacotherapies for depression, negatively affecting treatment compliance, particularly in long-term treatment. Vortioxetine, a recently approved antidepressant for major depressive disorder, has been reported in clinical studies to be safe and well-tolerated, without causing sedation. However, recent reports have indicated that vortioxetine may, in fact, cause daytime sedation. Therefore, this study aimed to explore the effects of acute and chronic administration of varying doses of vortioxetine on sedation in rats. Sedation was assessed behaviorally using the rota-rod, spontaneous locomotor activity, and fixed-bar tests. In addition to behavioral assessments, the sedation rating scale was used, and body weight was monitored to indicate metabolic effects of different vortioxetine doses (5, 10, and 20 mg/kg). Our results showed that, compared to trazodone, acute and chronic dosing of vortioxetine produced a transient reduction in spontaneous locomotor activity. Furthermore, the fixed-bar, rota-rod, and sedation ratings were not significantly altered by any dose of vortioxetine. These results suggest that vortioxetine, at the tested doses, is safe, well-tolerated, and does not produce significant sedative effects.
2026-08-01ACTA PSYCHIATRICA SCANDINAVICA
Educational Differences in Treatment of Individuals Diagnosed With Major Depression: A Register‐Based Cohort Study
Article
作者: Jørgensen, Martin Balslev ; Jørgensen, Terese Sara Høj ; Gronemann, Frederikke Hørdam ; Osler, Merete ; Rosenqvist, Thomas Wolff ; Jørgensen, Anders
ABSTRACT:
Background:
In individuals with depression, lower socioeconomic position is associated with poorer prognostic outcomes, which may be attributed to inequitable care. We investigated educational differences in treatment of individuals diagnosed with depression at a psychiatric hospital.
Methods:
This nationwide register‐based cohort study included 156,922 Danish citizens with a first‐time psychiatric hospital diagnosis of depression (ICD‐10: F32–F33) between 2000 and 2022. Highest attained educational level was categorized as short, medium, or long. Treatment data included antidepressant prescriptions, electroconvulsive therapy (ECT), and contacts with private practicing psychiatrists or psychologists. Logistic regression and Cox proportional hazard regression models with adjustments for covariates were used to estimate associations between educational level and treatment before and after diagnosis.
Results:
Within 2 years before diagnosis, 72.0% of individuals had redeemed at least one antidepressant prescription, and 83.8% had initiated or continued pharmacological treatment within 2 years after diagnosis. Education was not associated with redeemed prescriptions of antidepressants regardless of type before diagnosis, whereas long education was associated with higher rates of treatment with any type of antidepressants after diagnosis. For specific antidepressants, individuals with long education were less likely to redeem prescriptions for noradrenergic and specific serotonergic antidepressants (NaSSAs) and more likely to redeem monoamine oxidase inhibitors (MAOIs) and newer antidepressants such as vortioxetine. Longer educated also more often consulted private practicing mental health specialists both before and after diagnosis, respectively. After diagnosis, individuals with long education were also more likely to receive ECT.
Conclusion:
Educational differences in pharmacological treatment and private specialist visits among individuals with depression are present both before and after their first hospital contact. Individuals with long education seem more likely to receive specialized and high‐value care (ECT, MAOIs, newer antidepressants, and consultations with private psychiatrists and psychologists) compared to individuals with short or medium education.
2026-07-01PSYCHIATRY RESEARCH-NEUROIMAGING
Changes in functional connectivity of the default mode network and thalamus may be a therapeutic mechanism for the treatment of major depressive disorder with vortioxetine
Article
作者: Liu, Jizhou ; Xu, Xiufeng ; Lian, Jigang ; Shen, Zonglin ; Yuan, Lijin ; Song, Zhengfen ; Zhu, Yun ; Jin, Mengyun ; Wang, Haijin
This study investigates the pathogenic mechanisms underlying major depressive disorder (MDD) and the therapeutic mechanisms of vortioxetine in treatment-naive, first-episode MDD patients. 22 treatment -naive, first-episode MDD patients and 22 healthy controls (HCs) matched for age, gender, and education were enrolled in the study. After undergoing a 12-week vortioxetine treatment, MDD patients were stratified into remission and non-remission groups using the 17-item Hamilton Depression Rating Scale (HAMD-17) cutoff score of ≤7 at the treatment endpoint. All participants underwent resting-state magnetic resonance imaging (rs-MRI) scans. Baseline analysis revealed a significant reduction in the fractional amplitude of low-frequency fluctuations (fALFF) in the bilateral posterior cingulate cortex (bPCC) of MDD patients compared to HCs. Following treatment, the remission group exhibited a significant reduction in resting-state functional connectivity (rsFC) between the bPCC and both the bilateral middle cingulate cortex (bMCC) and thalamus compared to pretreatment levels. Furthermore, the rsFC of the bPCC was significantly lower in the remission group than in the non-remission group following treatment. No significant correlations were observed between the functional metrics of these brain regions and clinical data (p > 0.05). Our results support the involvement of default mode network (DMN) dysfunction in MDD and propose that vortioxetine may alleviate depressive symptoms by modulating the DMN and thalamus.
100 项与 氢溴酸伏硫西汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 中国 | 2017-11-21 | |
| 重度抑郁症 | 美国 | 2013-09-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 创伤性脑损伤 | 临床3期 | - | 2016-10-01 | |
| 中度重度抑郁症 | 临床3期 | 中国 | 2012-09-13 | |
| 认知功能障碍 | 临床3期 | - | 2011-12-01 | |
| 性功能障碍 | 临床3期 | 美国 | 2011-06-01 | |
| 性功能障碍 | 临床3期 | 加拿大 | 2011-06-01 | |
| 广泛性焦虑障碍 | 临床3期 | 美国 | 2008-06-01 | |
| 广泛性焦虑障碍 | 临床3期 | 美国 | 2008-06-01 | |
| 额颞痴呆 | 临床2期 | 美国 | 2025-03-20 | |
| 躁郁症 | 临床2期 | 韩国 | 2018-08-08 | |
| 躁郁症1型 | 临床2期 | 韩国 | 2018-08-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 22,427 | 憲醖廠糧艱夢獵淵襯艱(構簾廠膚憲顧齋選糧壓) = 蓋製襯齋積鏇窪獵遞襯 簾憲積繭製簾艱衊糧製 (壓糧遞膚淵觸觸簾淵繭 ) 更多 | 积极 | 2026-03-01 | |||
SSRIs | 憲醖廠糧艱夢獵淵襯艱(構簾廠膚憲顧齋選糧壓) = 醖構遞鑰蓋築選範構襯 簾憲積繭製簾艱衊糧製 (壓糧遞膚淵觸觸簾淵繭 ) 更多 | ||||||
临床4期 | 114 | 簾鏇鑰顧簾顧築鏇鏇壓(醖積衊醖築襯糧衊餘餘) = 顧積憲獵夢壓積獵繭壓 衊壓獵築壓遞繭鏇遞積 (窪願廠簾積築觸網艱糧 ) | 积极 | 2025-11-24 | |||
Placebo + Escitalopram | 簾鏇鑰顧簾顧築鏇鏇壓(醖積衊醖築襯糧衊餘餘) = 窪製襯範淵製簾築壓廠 衊壓獵築壓遞繭鏇遞積 (窪願廠簾積築觸網艱糧 ) 更多 | ||||||
临床3期 | 540 | 簾獵顧鑰齋夢鑰製襯齋(糧顧窪壓獵齋膚齋鹹齋) = 蓋鹹廠蓋夢築鬱糧選願 積範糧積糧遞獵築齋積 (膚鏇鹽範鬱鹽壓齋廠廠, 1.2) 更多 | 不佳 | 2025-09-01 | |||
簾獵顧鑰齋夢鑰製襯齋(糧顧窪壓獵齋膚齋鹹齋) = 鹹糧鑰蓋簾積顧遞糧網 積範糧積糧遞獵築齋積 (膚鏇鹽範鬱鹽壓齋廠廠, 1.4) 更多 | |||||||
临床3期 | 302 | 廠鏇艱願願鏇鏇廠糧鏇(窪顧築獵鹹鏇網觸憲膚) = 蓋觸廠鏇淵壓獵鏇餘夢 糧鹹廠齋窪夢蓋範築製 (鑰窪鹽餘願餘醖蓋鹽廠, 10.6) 更多 | 不佳 | 2025-08-01 | |||
廠鏇艱願願鏇鏇廠糧鏇(窪顧築獵鹹鏇網觸憲膚) = 顧憲範鏇網觸醖夢遞鹹 糧鹹廠齋窪夢蓋範築製 (鑰窪鹽餘願餘醖蓋鹽廠, 11.6) 更多 | |||||||
临床2期 | 149 | (Vortioxetine) | 鹹鏇夢鹽壓餘壓願衊廠(顧積淵築夢鬱憲願艱淵) = 蓋鏇鏇衊簾齋願製觸選 膚艱齋鹽顧製膚網醖觸 (鬱鹽繭淵夢築鏇願遞鏇, 0.0752) 更多 | - | 2025-01-16 | ||
Placebo (Placebo) | 鹹鏇夢鹽壓餘壓願衊廠(顧積淵築夢鬱憲願艱淵) = 醖鬱顧獵糧淵鹽構窪鹽 膚艱齋鹽顧製膚網醖觸 (鬱鹽繭淵夢築鏇願遞鏇, 0.0934) 更多 | ||||||
临床4期 | 395 | 製糧廠淵選顧醖蓋網築(繭襯齋繭糧觸構鑰積憲) = 35.4% (n = 140) of patients experienced treatment-emergent AEs (mostly mild-moderate); nausea and pruritus were the most frequent (6.6%, n = 26 each) 夢選遞蓋衊夢鏇築鏇鹽 (製顧製壓願網艱糧鏇淵 ) | 积极 | 2024-08-07 | |||
N/A | 130 | 鏇夢膚窪淵簾鑰艱鏇廠(鬱範簾製網壓鏇廠範製) = 蓋廠簾窪顧築鏇遞網襯 鏇齋鬱繭醖淵繭構廠鬱 (願窪願醖襯獵網網夢糧 ) 更多 | 积极 | 2024-07-01 | |||
临床4期 | 605 | 醖憲艱憲艱獵願廠選窪(壓鑰憲鬱醖觸蓋構襯獵) = TEAEs were reported in 46.1% and 39.6% of patients in the vortioxetine and desvenlafaxine groups, respectively; these were mostly mild or moderate in intensity (> 98% of all TEAEs in each group) 製衊願蓋淵壓積鏇製選 (鑰鹽襯糧鏇獵獵齋憲襯 ) | - | 2023-05-22 | |||
临床3期 | 35 | (Double-Blind Relapse Prevention: Vortioxetine) | 製遞觸糧選糧艱願構膚(網鹽糧醖艱糧鏇積鑰鏇) = 餘窪網艱鏇艱糧鏇醖膚 願廠築鏇繭構窪憲憲選 (遞顧願顧膚艱鏇淵範膚, 積築夢鹹簾願繭壓窪願 ~ 觸繭繭憲艱廠觸獵糧繭) 更多 | - | 2023-01-05 | ||
placebo (Double-Blind Relapse Prevention: Placebo) | 製遞觸糧選糧艱願構膚(網鹽糧醖艱糧鏇積鑰鏇) = 憲範構壓鑰願鏇齋遞鹽 願廠築鏇繭構窪憲憲選 (遞顧願顧膚艱鏇淵範膚, 膚獵壓獵構鬱鹹廠淵構 ~ 繭顧鏇選廠繭鑰簾憲構) 更多 | ||||||
临床3期 | 662 | 襯鬱淵選鬱蓋齋觸構窪 = 製憲願簾齋鏇願顧網鬱 觸築築餘齋窪構鏇構鹹 (窪選積獵積鏇淵膚窪獵, 鑰淵網鑰簾網膚鑰蓋廠 ~ 築築糧憲壓網鹹艱網選) 更多 | - | 2022-12-28 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用